Vyome (NASDAQ:HIND) Rating Increased to Hold at Wall Street Zen

Vyome (NASDAQ:HINDGet Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Thursday.

Several other equities analysts have also recently issued reports on the company. Maxim Group reissued a “buy” rating and issued a $15.00 price objective on shares of Vyome in a report on Thursday, October 2nd. Citigroup raised Vyome to a “buy” rating in a report on Thursday, October 2nd. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $15.00.

Check Out Our Latest Analysis on Vyome

Vyome Trading Down 5.5%

Vyome stock opened at $5.87 on Thursday. The stock has a market cap of $3.93 million, a price-to-earnings ratio of -0.01 and a beta of 1.05. Vyome has a fifty-two week low of $5.04 and a fifty-two week high of $720.00.

About Vyome

(Get Free Report)

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.

Read More

Receive News & Ratings for Vyome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyome and related companies with MarketBeat.com's FREE daily email newsletter.